Hepatomegaly Clinical Trial
Official title:
Prevalence of Hepatomegaly in Children and Adolescents With Type 1 Diabetes Mellitus Attending Assiut University Children Hospital
To assess the prevalence of hepatomegaly in children and adolescents with type 1 diabetes mellitus, and to find out it᾿s underlying etiology.
Type 1 diabetes is a disorder of glucose metabolism that results from insulin deficiency
secondary to autoimmune destruction of insulin-secreting β-cells. The prevalence of liver
disease among diabetics is estimated to be between 17% and 100%(1).
Most of these data were obtained from studies of obese adults with non-insulin dependent
diabetes(2). Data regarding frequency of aetiological causes of hepatomegaly in children and
adolescent with type 1 diabetes mellitus are scanty even in international publication(2).
Diabetes mellitus (DM) is associated with various structural and functional liver
abnormalities, including non-alcoholic fatty liver disease (NAFLD) and hepatic glycogenosis
(HG)(3).
NAFLD represents the most common liver disease(3) and is more typically found in obese adults
with T2DM secondary to insulin resistance, while (HG) is more common in patients with lower
body mass index and pediatric patients(4).
HG involves pathological glycogen storage in hepatocytes and is characterized by hepatomegaly
and a transient elevation in liver transaminases that is associated with poorly controlled
DM, particularly type 1 diabetes (T1D)(5).
The differential diagnosis of hepatomegaly in diabetic patients must consider several other
potential causes of liver damage, such as infection (e.g., viral hepatitis), metabolic
disorders (e.g., α1-antitrypsin deficiency and Wilson's disease), obstruction, autoimmune
liver disease, hemochromatosis and celiac disease(6).
Presence of hepatomegaly and/or hyperechogenic liver on ultrasound abdomen was an indication
for further laboratory work up to investigate other possible liver pathologies .The screening
work up included: HBV surface antigen, Anti-HCV antibody, serum immunoglobulins, anti-nuclear
antibody, smooth muscle antibody qualitative test , serum ferritin, serum iron, transferring
saturation, and total iron binding capacity, urine for organic acids and plasma for amino
acids, to evaluate for possibility of viral hepatitis B and C, autoimmune liver disease,
hemochromatosis, and metabolic disorder, respectively(7).
It was considered that the finding of hyperechogenic liver and/or hepatomegaly on ultrasound
and negative screening work up for underlying liver disease as consistent with a likely
diagnosis of hepatic glycogenosis or less likely fatty liver(8).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00565097 -
Lanreotide as Treatment of Polycystic Livers
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03801434 -
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
|
Phase 2 | |
| Terminated |
NCT02421354 -
Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
|
Phase 2 | |
| Active, not recruiting |
NCT03499808 -
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
|
Phase 2 | |
| Completed |
NCT00426153 -
Octreotide in Severe Polycystic Liver Disease
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT02298699 -
Biomarker for Sly Disease (MPS VII) (BioSly)
|
||
| Withdrawn |
NCT01331642 -
Biomarker for Gaucher Disease: BioGaucher (BioGaucher)
|
||
| Withdrawn |
NCT02298634 -
Biomarker for Farber Disease (BioFarber)
|
||
| Active, not recruiting |
NCT00771888 -
Open-Label Extension of LOCKCYST Trial
|
Phase 2/Phase 3 |